Intralesional Injection of STS in Treatment of Calcinosis

Launched by ROBYN T. DOMSIC, MD, MPH · Nov 1, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for people who have calcinosis, which is the buildup of calcium deposits in the skin, often seen in conditions like systemic sclerosis, dermatomyositis, and mixed connective tissue disease. The researchers want to see if injecting a medication called STS directly into these calcium deposits can help reduce their size and improve symptoms. The injections will be guided by ultrasound, and the effectiveness will be measured using both imaging and feedback from participants about their symptoms.

To participate in this trial, you need to be at least 18 years old and have a diagnosis of one of the mentioned conditions, along with evidence of calcinosis shown through an X-ray or ultrasound. It's important that participants are able to understand the study and provide their consent. Pregnant women cannot join the study. If you qualify, you can expect to receive treatment and be monitored for any changes in your condition over time. This trial is currently looking for volunteers, so it's an opportunity to contribute to research that could help others in similar situations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical diagnosis of systemic sclerosis, mixed connective tissue disease or inflammatory myopathy
• • Must be over 18 years of age
• • Participants must be competent to give informed consent
• • Participants must have radiographic evidence (xray or ultrasound) of calcinosis.
• • Participants must need symptomatic relief
• Exclusion Criteria:
• • • Pregnant women will be excluded